Inactivated piscine orthoreovirus vaccine
AssigneeIntervet Inc.
InventorsJohanna Jacoba Elisabeth Bijlsma, Sven Leininger, Stephane Villoing
Life of this patent
Estimating the term…
Abstract
The invention derives from the discovery that the immunogenicity of piscine orthoreovirus (PRV) can be significantly increased by inactivating the virus in a way different from the prior art: by incubation with an aziridine the vaccine potency against challenge infection by cohabitation is much improved over prior art approaches. This allowed the development of an effective inactivated vaccine against infection and disease caused by PRV.
Claims17
A composition comprising an inactivated orthoreovirus, that has been inactivated by incubation with an aziridine, wherein the orthoreovirus is piscine orthoreovirus (PRV).
A method of producing a composition comprising aziridine-inactivated piscine orthoreovirus (PRV), comprising the steps of:
- a. obtaining a composition comprising PRV, and
- b. inactivating the PRV in said composition by incubation with an aziridine.
Dependencies are inferred from the claim text.